ViBA

Characterizing Apixaban Pharmacokinetics Through Physiologically-Based Pharmacokinetic Modeling: Critical Role of Biliary Secretion and Enterohepatic Circulation in Humans.

Tsuchitani T, Kou W, Tomi M · CPT: pharmacometrics & systems pharmacology · 2026 · Article

10.1002/psp4.70163

Verified evidence

Pharmacokinetic scenario comparison

13d5fbd0-b3f0-56eb-846a-f0eb643bca1d
Area under the curve (AUC)Pharmacokinetics and drug exposure

Prediction source Version of record · PDF page(s) 4, 7

Study 4ba38d4f-0a22-5201-8423-04201e49e386 · Prediction record (JSON)

Prediction fields

Endpoint
elimination_half_life · PDF page(s) 4, 7
Family
pharmacokinetic_exposure · PDF page(s) 4, 7
Measured variable
elimination_half_life · PDF page(s) 4, 7
Metric
fraction · PDF page(s) 4
Model
mechanistic_or_numerical · PDF page(s) 1, 4, 7
Population
simulated_system · PDF page(s) 1, 4, 7
Unit
hour · PDF page(s) 4, 7

psp470163-sup-0001-supinfo.txt · Publisher supplement · psp470163-sup-0001-supinfo.txt · Prediction-linked resource · PDF page 10 · Public availability reported by the authors · Primary file reviewed

Apixaban whole-body PBPK model source · Wiley supporting information · Data S1 (psp470163-sup-0001-supinfo.txt) · Prediction-linked resource · PDF page 3 · Availability reported by the authors · Curated resource record

Validation Related evidence · Unknown · Unknown · Not assessed · Partially comparable · Not applicable